MCY-M11

MCY-M11

MaxCyte is evaluating its first autologous CAR drug candidate in mesothelin-expressing solid tumors. This product candidate, MCY-M11, employs repeat infusions of mesothelin-specific human mRNA CAR-transfected into peripheral blood mononuclear cells (PBMCs) to allow for “controlled persistence.” Early non-clinical testing has provided preliminary evidence of the anti-tumor activity of this drug.

MaxCyte and its collaborators at the Johns Hopkins Kimmel Cancer Center explored the various attributes of MCY-M11 in nonclinical studies. In a murine ovarian cancer model, a single intra-peritoneal (IP) injection of MCY-M11 resulted in the dose-dependent inhibition of tumor growth and prolonged the overall survival (OS) of the mice in the study. Weekly IP (intra-peritoneal) injections of the optimized MCY-M11 dose boosted disease control and further prolonged OS, both of which improved with an increasing number of injections. No significant off-tumor toxicities were observed.

A Phase 1 clinical study, CP-M11-101, titled “A Phase 1 Study of Intraperitoneal MCY-M11 Therapy for Women with Platinum Resistant High Grade Serous Adenocarcinoma of the Ovary, Primary Peritoneum, or Fallopian Tube, or Subjects with Peritoneal Mesothelioma with Recurrence After Prior Chemotherapy” is underway. For details on this study, please visit clinicaltrials.gov.

2017 AACR Annual Meeting Abstract: Development of anti-human mesothelin chimeric antigen receptor (CAR) messenger RNA (mRNA) transfected peripheral blood mononuclear cells (CARMA) for the treatment of mesothelin-expressing cancers

Learn about cutting-edge applications, new resources, and upcoming events.
Subscribe to our e-Newsletter

Request Demo